We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Spectral Provides Update on its EUPHRATES Trial

Spectral Provides Update on its EUPHRATES Trial

Spectral Provides Update on its EUPHRATES Trial

Spectral Provides Update on its EUPHRATES Trial

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Spectral Provides Update on its EUPHRATES Trial"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Spectral Diagnostics Inc. has announced that 156 patients have now been randomized in its EUPHRATES trial. The trial is currently enrolling patients at 40 sites, operating in 45 hospitals in North America.

In addition, patient recruitment rates have been higher than anticipated. Consequently, the trial is on track to enroll the 184 patients required for its second interim analysis before the end of 2013.

"Our clinical team and our fully engaged study sites are focused on maintaining enrolment at a consistent and robust rate that will allow us to complete the trial by the end of 2014 based on the existing sample size of 306 evaluable patients," said Ms. Debra Foster, Spectral's Vice President of Clinical Development.

Ms. Foster continued, "The composite 28-day mortality rate of 33 per cent for randomized patients continues to suggest that we are enrolling patients in the trial who are at greatest risk for a poor outcome and, therefore, would most likely benefit from our treatment."

"We are eagerly anticipating the results of the second interim analysis, which we believe will allow us to plan for the successful completion of the trial," stated Dr. Paul Walker, President and CEO of Spectral. "This represents a very important clinical and commercial milestone for the Company."

At the second interim analysis, the Data and Safety Monitoring Board will advise the Company on the trial's safety, efficacy or futility, with stopping rules in place for efficacy and futility. A sample size recalculation will be done if necessary.